Odyssean LLC increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 192.6% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 60,005 shares of the company’s stock after purchasing an additional 39,495 shares during the period. Odyssean LLC owned about 0.08% of Vera Therapeutics worth $2,575,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in VERA. Los Angeles Capital Management LLC purchased a new stake in shares of Vera Therapeutics in the fourth quarter valued at $46,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at $71,000. Quantbot Technologies LP purchased a new position in shares of Vera Therapeutics during the second quarter valued at $51,000. Nykredit A S acquired a new position in Vera Therapeutics during the second quarter valued at $97,000. Finally, Sandia Investment Management LP acquired a new position in Vera Therapeutics during the fourth quarter valued at $127,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on VERA shares. The Goldman Sachs Group restated a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wedbush reissued a “neutral” rating and issued a $34.00 price target on shares of Vera Therapeutics in a research report on Monday, August 17th. Bank of America raised their price target on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Needham & Company LLC set a $125.00 price objective on shares of Vera Therapeutics in a research note on Wednesday, July 8th. Finally, William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $81.15.
Vera Therapeutics Stock Performance
Shares of VERA stock opened at $35.28 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. Vera Therapeutics, Inc. has a fifty-two week low of $21.15 and a fifty-two week high of $56.05. The stock’s 50-day moving average is $36.34 and its two-hundred day moving average is $37.86. The firm has a market cap of $2.54 billion, a P/E ratio of -6.02 and a beta of 0.92.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the previous year, the company earned ($1.20) EPS. Analysts predict that Vera Therapeutics, Inc. will post -6.43 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.
Vera Therapeutics Profile
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Featured Articles
- Five stocks we like better than Vera Therapeutics
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
